Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with chemotherapy in locally advanced breast cancer
NCT00574587Phase 2Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Dec 2007
- Primary completion
- May 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in breast cancer, sponsored by Albert Einstein College of Medicine. Primary endpoint: Recommended Phase II Dose at 3 weeks. Started Dec 2007; status: completed.
02
Drugs
vorinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00574587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574587.